Neuroprotective Peptides for Retinal Ganglion Cells

Glaucoma Peptides

67% axon loss

A 40% IOP elevation for three weeks caused 67% degradation in RGC axonal transport; a single collagen mimetic peptide injection significantly reduced this damage.

Ribeiro et al., Int J Mol Sci, 2022

Ribeiro et al., Int J Mol Sci, 2022

View as image

Glaucoma destroys vision by killing retinal ganglion cells (RGCs), the neurons whose axons form the optic nerve and carry visual information from the eye to the brain. Current treatments focus almost exclusively on lowering intraocular pressure (IOP), but RGC death continues in many patients even after IOP is controlled. This has driven a search for neuroprotective strategies that directly protect RGCs from degeneration, and peptides have emerged as one of the most promising therapeutic classes for this purpose. Several peptide-based approaches have shown efficacy in animal models of glaucoma, from small chaperone peptides that cross the blood-retinal barrier to collagen mimetics that repair damaged axonal environments. For the broader role of peptides in glaucoma, including endothelin's contribution to the disease, see the pillar article on endothelin and glaucoma.

Why RGCs Die in Glaucoma

Retinal ganglion cells are uniquely vulnerable neurons. Their cell bodies sit in the innermost layer of the retina, and their axons extend through the optic nerve head, a mechanically constrained region where they are exposed to pressure-related stress, vascular insufficiency, and metabolic compromise.^[4]

Elevated IOP, the primary modifiable risk factor for glaucoma, damages RGCs through several interconnected mechanisms: mechanical compression of axons at the lamina cribrosa, disruption of axonal transport (cutting off neurotrophic factor delivery from the brain to the retina), mitochondrial dysfunction from metabolic stress, microglial activation that produces neuroinflammatory mediators, and activation of apoptotic signaling cascades. Current IOP-lowering drugs (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors) address only the mechanical trigger. They do nothing to protect RGCs from the downstream cascade of damage that continues even after pressure is normalized.

This is why neuroprotection matters: an estimated 25-30% of glaucoma patients continue to lose vision despite achieving target IOP levels. These patients need something that directly protects RGC survival and axonal integrity. The human retina contains approximately 1.2 million RGCs at birth, and once lost, they do not regenerate. Every RGC that dies takes with it a piece of the visual field that cannot be recovered with any current technology.

Peptain-1: A Chaperone Peptide That Crosses the Blood-Retinal Barrier

One of the most practical challenges in ocular neuroprotection is drug delivery. The blood-retinal barrier prevents most systemically administered compounds from reaching the retina, and intravitreal injections (directly into the eye) are invasive and impractical for a chronic disease requiring ongoing treatment.

Stankowska and colleagues (2019) demonstrated that peptain-1, a small peptide derived from the alpha-crystallin chaperone protein family, crosses the blood-retinal barrier after intraperitoneal injection.^[1] Using Cy7 fluorophore conjugation, they confirmed peptain-1's presence in the retina after systemic administration. The peptide exhibits robust chaperone and anti-apoptotic activities.

In cultured rat primary RGCs and retinal explants, peptain-1 significantly decreased hypoxia-induced RGC loss compared to a scrambled control peptide. In mice subjected to ischemia/reperfusion injury (an acute model), peptain-1 treatment inhibited RGC loss and ameliorated reduction in anterograde axonal transport. In a chronic model (rats with five weeks of elevated IOP), intraperitoneal peptain-1 significantly reduced RGC death and axonal loss while partially restoring retinal mitochondrial cytochrome c oxidase subunit 6b2 (COX 6b2) levels, suggesting a mechanism involving mitochondrial protection.^[1]

The ability to protect RGCs via systemic injection is significant because it would allow oral or subcutaneous dosing rather than repeated eye injections, making long-term treatment practical. Peptain-1's mechanism involves chaperone activity (preventing protein aggregation under stress) and direct anti-apoptotic signaling, which addresses two pathways simultaneously. The partial restoration of mitochondrial COX 6b2 levels is relevant because mitochondrial dysfunction in RGCs is increasingly recognized as an early event in glaucomatous damage, occurring before visible structural changes on clinical imaging.^[1]

Collagen Mimetic Peptides: Repairing the Axonal Environment

RGC axon degeneration involves matrix metalloproteinase (MMP)-mediated remodeling of the collagen-rich extracellular environment through which axons travel. Rather than targeting the neuron directly, collagen mimetic peptides (CMPs) target the damaged extracellular matrix.

Ribeiro and colleagues (2022) tested a CMP comprising single-strand fractions of triple helix human type I collagen in both chronic and acute optic nerve injury models.^[2] In an inducible glaucoma model, a three-week 40% elevation in IOP caused a 67% degradation in anterograde transport to the superior colliculus (the primary retinal projection target in rodents). A single intravitreal injection of CMP during the period of IOP elevation significantly reduced this degradation.^[2]

The same CMP also promoted significant axonal recovery when delivered shortly after optic nerve crush, an acute injury model. In the optic nerve crush model, CMP delivery shortly after injury promoted significant axonal recovery during the two-week period following injury, indicating reparative capacity beyond simple protection.^[2] This dual efficacy in both chronic (glaucoma) and acute (trauma) settings suggests that repairing the collagen matrix around axons creates a permissive environment for both protection and regeneration. The CMP approach is mechanistically distinct from traditional neuroprotection because it targets the extracellular environment rather than intracellular signaling pathways, potentially making it complementary to other neuroprotective peptides.

ONL1204: A Fas Receptor Inhibitor With Anti-Inflammatory Effects

Fas-FasL signaling is a major apoptotic pathway in glaucomatous RGC death, but it also drives microglial activation and neuroinflammation. Krishnan and colleagues (2019) tested ONL1204, a small peptide antagonist of the Fas receptor, in a microbead-induced mouse model of glaucoma.^[3]

At 28 days post-microbead injection (with sustained IOP elevation), ONL1204 significantly reduced RGC death and axon loss compared to vehicle-treated controls. The peptide was effective even when administered 7 days after IOP elevation had begun, a clinically relevant finding since glaucoma patients are typically diagnosed after damage has already started.

ONL1204 also produced striking anti-inflammatory effects. Confocal analysis of retinal flatmounts showed abrogated microglial activation, and quantitative PCR confirmed inhibition of multiple inflammatory genes implicated in glaucoma: cytokines (TNF-alpha, IL-1-beta, IL-6, IL-18), chemokines (MIP-1-alpha, MIP-1-beta, MIP-2, MCP1, IP10), complement cascade components (C3, C1Q), Toll-like receptor pathway (TLR4), and inflammasome pathway (NLRP3).^[3]

The breadth of inflammatory pathway suppression is notable. Glaucoma researchers increasingly view neuroinflammation as both a cause and consequence of RGC death, creating a vicious cycle. ONL1204 appears to break this cycle at the Fas receptor level, simultaneously blocking apoptosis and the inflammatory cascade.

GLP-1 Receptor Agonists: An Unexpected Connection

The most surprising recent development in glaucoma neuroprotection comes from the metabolic peptide field. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide), developed for type 2 diabetes and obesity, show unexpected neuroprotective effects in the retina.

Mouhammad and colleagues (2026) demonstrated that semaglutide protected retinal ganglion cells against rotenone-induced degeneration (a mitochondrial complex I inhibitor that models metabolic stress in RGCs) via improved glucose metabolism.^[4] GLP-1 receptors are expressed on retinal neurons, and semaglutide's neuroprotective effect appears to operate through metabolic rescue rather than direct anti-apoptotic signaling.

A 2025 review by Lang and colleagues examined the emerging epidemiological and preclinical evidence linking GLP-1 receptor agonist use to reduced glaucoma risk.^[5] The review found converging evidence from population-level data (patients on GLP-1 agonists for diabetes showing lower glaucoma incidence) and laboratory studies showing RGC protection in multiple glaucoma models.

This GLP-1 connection is particularly interesting because millions of people are already taking these drugs for weight loss and diabetes. If the neuroprotective effect is confirmed in prospective studies, glaucoma risk reduction could become a recognized secondary benefit of metabolic peptide therapy. However, no clinical trial has tested GLP-1 agonists specifically for glaucoma outcomes.

The Neurotrophic Factor Gap

The best-characterized endogenous neuroprotective agents for RGCs are neurotrophic factors: BDNF, CNTF, and NGF. BDNF is the most extensively studied, and exogenous BDNF delivery consistently reduces RGC loss in acute and chronic glaucoma models. A Phase I clinical trial of a sustained-release CNTF intraocular implant enrolled 11 patients with primary open-angle glaucoma with no serious adverse events. Topical NGF drops have also entered early clinical testing and were deemed safe.

The challenge is sustained delivery. Neurotrophic factors are large proteins with short half-lives that do not cross the blood-retinal barrier. Intravitreal injection provides only transient protection, and repeated injections carry risks of infection, retinal detachment, and patient burden. Gene therapy approaches using AAV vectors to deliver BDNF or CNTF genes to retinal cells show promise for sustained expression, but none have progressed beyond preclinical testing for glaucoma.

The small peptides described in this article (peptain-1, CMPs, ONL1204) have practical advantages over full-length neurotrophic factors: they are smaller, more stable, can potentially cross the blood-retinal barrier, and are cheaper to manufacture. They represent a different strategic approach: rather than replacing what the retina has lost (neurotrophic support), they target specific pathogenic mechanisms (apoptosis, matrix degradation, neuroinflammation) that drive RGC death. In theory, combining a neurotrophic factor (to provide survival signals) with one of these small peptides (to block a death pathway) could produce additive or synergistic neuroprotection, though no study has tested such combinations in glaucoma models.

For more on how BDNF supports neuronal survival throughout the nervous system, see our article on BDNF, the brain peptide that builds new neural connections. The sibling article on peptide approaches to glaucoma covers IOP-lowering peptide strategies.

How Close Are These to Clinical Use?

None of the peptide-based neuroprotective strategies described here have entered Phase II or Phase III clinical trials for glaucoma. The field faces several structural challenges:

Clinical trial design is difficult. Glaucoma progresses slowly over years to decades. Proving that a neuroprotective agent slows RGC loss requires large, long-duration trials with sophisticated imaging endpoints (optical coherence tomography, visual field testing). This makes trials expensive and risky for sponsors.

The IOP-lowering standard is hard to beat. Regulators and clinicians are reluctant to test neuroprotective agents as monotherapy when IOP-lowering drugs are effective. Most trial designs would require neuroprotection as add-on therapy to standard care, which requires even larger sample sizes to detect an incremental benefit.

Delivery challenges persist. Peptain-1's systemic bioavailability is promising but needs human pharmacokinetic validation. CMPs and ONL1204 currently require intravitreal injection, which limits their practical utility for a chronic disease.

The GLP-1 agonist pathway may be the fastest to clinical relevance, not because of peptide-specific glaucoma trials, but because retrospective analyses of patients already taking semaglutide or tirzepatide could provide epidemiological evidence of glaucoma risk reduction. If confirmed, this could prompt prospective trials with far less regulatory friction than a novel peptide would require. The metabolic mechanism also raises questions about whether the neuroprotective benefit extends to normal-tension glaucoma, a variant where IOP is within the normal range but RGC death still occurs, potentially through vascular or metabolic insufficiency.

The Bottom Line

Multiple peptide-based strategies show preclinical promise for protecting retinal ganglion cells in glaucoma: peptain-1 crosses the blood-retinal barrier systemically, collagen mimetic peptides repair the damaged axonal environment, ONL1204 blocks both apoptosis and neuroinflammation through Fas receptor inhibition, and GLP-1 agonists offer metabolic neuroprotection. None have completed clinical trials for glaucoma, and the slow disease progression, delivery challenges, and high clinical trial costs remain significant barriers to translation.

Frequently Asked Questions

What peptides protect retinal ganglion cells?

Several peptides have shown neuroprotective effects on retinal ganglion cells in animal models of glaucoma. Peptain-1, derived from alpha-crystallin, crosses the blood-retinal barrier and reduces RGC death after systemic injection (Stankowska et al., 2019). ONL1204, a Fas receptor inhibitor peptide, blocks both apoptosis and neuroinflammation (Krishnan et al., 2019). Collagen mimetic peptides repair the damaged extracellular matrix around RGC axons (Ribeiro et al., 2022). None have completed human clinical trials for glaucoma.

Can semaglutide help with glaucoma?

Semaglutide protected retinal ganglion cells against metabolic stress in laboratory models by improving glucose metabolism (Mouhammad et al., 2026). Epidemiological evidence suggests patients taking GLP-1 agonists for diabetes may have lower glaucoma incidence (Lang et al., 2025). No clinical trial has tested semaglutide specifically for glaucoma outcomes. The connection is plausible but unproven in humans.

Why don't current glaucoma drugs protect retinal ganglion cells?

Current glaucoma medications (prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors) work by lowering intraocular pressure. They do not directly protect retinal ganglion cells from the downstream cascade of damage (apoptosis, neuroinflammation, mitochondrial dysfunction, axonal transport failure) that continues even after pressure is controlled. An estimated 25-30% of patients continue losing vision despite achieving target IOP.

What is neuroinflammation in glaucoma?

Neuroinflammation in glaucoma involves activation of retinal microglia (resident immune cells) that produce inflammatory cytokines (TNF-alpha, IL-1-beta, IL-6), complement cascade components, and inflammasome pathway mediators. This inflammatory response both results from and accelerates retinal ganglion cell death, creating a vicious cycle. The Fas receptor inhibitor peptide ONL1204 suppressed multiple inflammatory pathways in a mouse glaucoma model (Krishnan et al., 2019).

Is there a neuroprotective treatment for glaucoma?

No neuroprotective drug is currently approved for glaucoma treatment. Several peptide-based approaches have shown efficacy in animal models, and neurotrophic factors (BDNF, CNTF, NGF) are in early clinical testing. A CNTF sustained-release implant completed a Phase I safety trial in 11 glaucoma patients. The slow progression of glaucoma makes clinical trials expensive and time-consuming, which has slowed drug development.